Table 1.
Patient characteristics for patients with axial spondyloarthritis (SpA)
| Characteristics | Axial SpA (n = 83) |
|---|---|
| Age (years) | 38 (30–43) |
| Gender (percentage female) | 58 |
| HLA‐B27 (percentage positive) | 61 |
| Disease duration (years) | 7·5 (5·0–11·0) |
| Treatment (percentage of patients) | |
| Methotrexate | 11 |
| Salazopyrin | 12 |
| TNF‐α inhibitor | 8 |
| Self‐assessment scores | |
| BASDAI (0–100) | 29 (11–51) |
| BASFI (0‐100) | 15 (4–33) |
| Patient global (0–100) | 24 (7‐52) |
| Clinical scores | |
| BASMI (0–100) | 0 (0–0) |
| Physician global (0–100) | 10 (5–23) |
| Test results | |
| CRP (mg/l) | 2·1 (1·3–3·9) |
| SIJ MRI activity (0–40) | 5 (2–13) |
| Spine MRI activity (0–81) | 1 (0–4) |
| SIJ MRI chronicity (0–48) | 11 (2–27) |
| Spine MRI chronicity (0–207) | 0 (0–4) |
Numbers and parentheses express median and interquartile range (IQR). TNF‐α = tumour necrosis factor‐alpha; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondilitis Metrology Index; CRP = C‐reactive protein; MRI = magnetic resonance imaging; SIJ = sacroiliac joint; HLA = human leucocyte antigen.